Dong-A ST Co., Ltd. Stock price

Equities

A170900

KR7170900005

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
76,600 KRW -0.78% Intraday chart for Dong-A ST Co., Ltd. +5.08% +10.85%
Sales 2024 * 647B 480M Sales 2025 * 689B 511M Capitalization 650B 482M
Net income 2024 * 32B 23.74M Net income 2025 * 36B 26.71M EV / Sales 2024 * 1.16 x
Net Debt 2024 * 101B 75.13M Net Debt 2025 * 82.05B 60.88M EV / Sales 2025 * 1.06 x
P/E ratio 2024 *
22.3 x
P/E ratio 2025 *
18.8 x
Employees 1,662
Yield 2024 *
1.03%
Yield 2025 *
0.98%
Free-Float 51.69%
More Fundamentals * Assessed data
Dynamic Chart
Dong-A ST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd. CI
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara CI
Dong-A ST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
MEZOO Co.,Ltd. announced that it has received KRW 18 billion in funding from a group of investors CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023. CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023. CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on July 26, 2023, has closed with 38,373 shares, representing 0.45% for KRW 2,296.31 million. CI
Dong-A ST Sets Sight on European Market with Stelara Biosimilar Expansion MT
Dong-A ST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 38,373 shares. CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023. CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023. CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan. CI
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar CI
More news
1 day-0.78%
1 week+5.08%
Current month+2.27%
1 month+9.12%
3 months+13.48%
6 months+30.22%
Current year+10.85%
More quotes
1 week
72 300.00
Extreme 72300
79 500.00
1 month
71 200.00
Extreme 71200
88 000.00
Current year
64 200.00
Extreme 64200
88 000.00
1 year
47 745.10
Extreme 47745.098
88 000.00
3 years
45 271.05
Extreme 45271.0496
97 078.05
5 years
45 271.05
Extreme 45271.0496
114 859.67
10 years
45 271.05
Extreme 45271.0496
174 452.13
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 -
President 55 -
Director/Board Member 53 -
Members of the board TitleAgeSince
Director/Board Member 50 -
Chief Executive Officer 52 -
Director/Board Member 54 -
More insiders
Date Price Change Volume
24-03-28 74,800 -2.35% 41,744
24-03-27 76,600 -0.78% 46,036
24-03-26 77,200 +2.80% 101,960
24-03-25 75,100 +1.49% 65,365
24-03-22 74,000 +0.82% 44,319

End-of-day quote Korea S.E., March 26, 2024

More quotes
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Dong-A ST Co., Ltd. - Korea S.E.